Healthcare distributor and services company McKesson (NYSE: MCK) reported calendar Q3 2026 (fiscal Q2 2027) results exceeding the market’s revenue expectations, with sales up 7.6% year on year to $111 billion. Its non-GAAP profit of $11.68 per share was 8.6% above analysts’ consensus estimates.

Is now the time to buy MCK? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

McKesson’s results in the third quarter reflected continued momentum in its core pharmaceutical distribution and specialty services. Management highlighted strong performance from North American Pharmaceutical and Oncology & Multispecialty, driven by higher prescription volume—including GLP-1 medications—and provider platform growth. CEO Brian Tyler underscored the strategic value of recent acquisitions, noting, “Our acquisition of Precision Medicine Group adds global clinical research and commercialization capabilities, expanding our ability to support biopharma partners.” While operational leverage and diversified growth supported non-GAAP earnings, the company faced headwinds from lower branded pharmaceutical pricing and branded-to-generic conversions, which partially offset top-line gains.

Looking ahead, McKesson raised its full-year adjusted earnings outlook, citing strong execution and confidence in its strategic investments. Management pointed to accelerated investments in automation, technology, and specialty services as key drivers for future growth. CFO Kenny Cheung stated, “Our updated guidance reflects broad-based strength across the business, with ongoing investments in automation and technology expected to support operational leverage.” The company also emphasized the long-term opportunity in home and community-based care, with investments in Option Care Health positioned to expand McKesson’s reach in specialty and alternate site infusion services. Management acknowledged ongoing policy uncertainty and the evolving payer landscape as factors they are actively monitoring.

Key insights from management’s remarks

Management attributed the results to broad-based growth in specialty distribution, recent acquisitions, and operational efficiencies, while cautioning about policy and payer environment uncertainty.

• Specialty distribution momentum: Growth in specialty pharmaceuticals, including GLP-1 medications for weight management and diabetes, was a primary revenue driver. Management credited robust demand and expanded distribution capabilities for this momentum.
• Oncology & provider platform expansion: The addition of new providers and strong utilization trends in the Oncology & Multispecialty segment supported both revenue and operating profit growth. Same-store patient visits reached recent highs, and new acquisitions, such as Precision Medicine Group, further broadened the segment’s clinical and research expertise.
• Prescription technology solutions scaling: Increased demand for prior authorization and access solutions in the Prescription Technology segment drove segment growth, particularly through automation and expanded payer connectivity. The CMS Medicare GLP-1 Bridge program contributed to volumes, though management noted normalization following early spikes.
• Operational leverage and cost discipline: Operating expenses grew in line with gross profit, allowing for margin stability despite rising cost pressures and increased investments in technology and supply chain enhancements.
• Portfolio transformation via M&A: The acquisitions of Precision Medicine Group and a planned investment in Option Care Health were highlighted as key strategic moves to bolster McKesson’s position in biopharma services and home-based care. Management expects these deals to provide long-term adjacencies and incremental earnings, with integration complexity viewed as manageable due to complementary capabilities.

Drivers of future performance

McKesson’s outlook is anchored by continued specialty growth, automation investments, and expansion into community-based and home infusion care.

• Specialty and automation investments: Management expects ongoing demand for specialty pharmaceuticals and automation in supply chain and prescription solutions to sustain revenue growth. Investments in technology are aimed at driving productivity and operational leverage, even as the company enters new therapeutic areas and payer models.
• M&A integration and new platforms: The integration of Precision Medicine Group is anticipated to enhance McKesson’s clinical trial and commercialization offerings, while the Option Care Health investment is positioned to expand community and home-based infusion services. Management views these platforms as accretive to future non-GAAP earnings and as broadening the company’s long-term growth profile.
• Policy and market environment risks: Executives cautioned about ongoing policy uncertainty, particularly with potential changes to the 340B drug pricing program and payer reimbursement structures. Management emphasized its diversified channel presence as a buffer, but acknowledged that regulatory shifts could impact both volumes and margins in future periods.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) the pace and financial impact of integrating Precision Medicine Group into Oncology & Multispecialty, (2) progress toward closing and operationalizing the Option Care Health investment, and (3) the resilience of specialty pharmaceutical demand, especially GLP-1s, amid potential policy changes. Developments in the regulatory environment and customer contract renewals will also serve as important indicators of execution.

McKesson currently trades at $1,040, down from $1,067 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.